Compare Stocks

Date Range: 

 Cryo-Cell InternationalBaudax BioGreenVision AcquisitionEmmaus Life SciencesCaladrius Biosciences
SymbolOTCMKTS:CCELNASDAQ:BXRXNASDAQ:GRNVOTCMKTS:EMMANASDAQ:CLBS
Price Information
Current Price$8.50$0.88$10.15$1.23$1.52
52 Week RangeN/ABuyN/AN/ABuy
MarketRank™
Overall Score1.01.40.30.21.5
Analysis Score0.03.50.00.03.4
Community Score2.32.80.00.02.7
Dividend Score0.00.00.00.00.0
Ownership Score1.70.01.70.80.0
Earnings & Valuation Score1.30.60.00.01.3
Analyst Ratings
Consensus RecommendationN/ABuyN/AN/ABuy
Consensus Price TargetN/A$13.50N/AN/A$10.00
% Upside from Price TargetN/A1,428.71% upsideN/AN/A557.89% upside
Trade Information
Market Cap$64.35 million$61.94 million$72.96 million$60.25 million$90.44 million
Beta0.292.56N/A2.341.55
Average Volume9,2504,823,413121,28414,2584,901,891
Sales & Book Value
Annual Revenue$31.80 millionN/AN/A$1.32 millionN/A
Price / Sales2.02N/AN/A45.65N/A
Cashflow$0.39 per shareN/AN/AN/AN/A
Price / Cash21.68N/AN/AN/AN/A
Book Value($0.89) per shareN/AN/AN/A$1.98 per share
Price / Book-9.55N/AN/AN/A
Profitability
Net Income$2.29 million$-32,560,000.00N/A$-2,370,000.00$-19,360,000.00
EPSN/A($3.48)N/AN/A($1.88)
Trailing P/E Ratio21.25N/A0.000.00N/A
Forward P/E RatioN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins10.39%N/AN/AN/AN/A
Return on Equity (ROE)-58.74%N/AN/AN/A-68.33%
Return on Assets (ROA)7.30%N/AN/AN/A-57.61%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/AN/AN/AN/A
Current Ratio1.16%1.45%1.03%N/A9.87%
Quick Ratio1.08%1.36%1.03%N/A9.87%
Ownership Information
Institutional Ownership Percentage0.98%7.86%67.72%0.12%8.99%
Insider Ownership Percentage53.80%13.10%N/A36.88%10.30%
Miscellaneous
Employees8957N/A2824
Shares Outstanding7.57 million70.14 million7.19 million48.99 million59.50 million
Next Earnings Date7/9/2021 (Estimated)8/9/2021 (Estimated)N/AN/A8/12/2021 (Estimated)
OptionableNot OptionableNot OptionableNot OptionableNot OptionableOptionable
SourceHeadline
Caladrius Biosciences (NASDAQ:CLBS) Announces Quarterly  Earnings ResultsCaladrius Biosciences (NASDAQ:CLBS) Announces Quarterly Earnings Results
americanbankingnews.com - May 8 at 11:54 PM
Caladrius Biosciences, Inc. (CLBS) CEO David Mazzo on Q1 2021 Results - Earnings Call TranscriptCaladrius Biosciences, Inc. (CLBS) CEO David Mazzo on Q1 2021 Results - Earnings Call Transcript
seekingalpha.com - May 8 at 11:05 PM
Caladrius Biosciences, Inc. (CLBS) Reports Q1 Loss, Lags Revenue EstimatesCaladrius Biosciences, Inc. (CLBS) Reports Q1 Loss, Lags Revenue Estimates
msn.com - May 6 at 9:55 PM
Caladrius Biosciences Reports First Quarter 2021 Financial Results and Provides Business UpdateCaladrius Biosciences Reports First Quarter 2021 Financial Results and Provides Business Update
finance.yahoo.com - May 6 at 4:54 PM
Caladrius Biosciences (CLBS) Scheduled to Post Quarterly Earnings on ThursdayCaladrius Biosciences (CLBS) Scheduled to Post Quarterly Earnings on Thursday
americanbankingnews.com - May 5 at 6:58 AM
Caladrius Biosciences Announces Participation in Upcoming Virtual Conferences in May 2021Caladrius Biosciences Announces Participation in Upcoming Virtual Conferences in May 2021
finance.yahoo.com - May 4 at 10:16 AM
Selling your Caladrius Biosciences, Inc. (NASDAQ:CLBS) stock? Here’s what you need to knowSelling your Caladrius Biosciences, Inc. (NASDAQ:CLBS) stock? Here’s what you need to know
stocksregister.com - May 1 at 6:06 PM
Caladrius Biosciences (CLBS) Set to Announce Quarterly Earnings on ThursdayCaladrius Biosciences (CLBS) Set to Announce Quarterly Earnings on Thursday
americanbankingnews.com - April 30 at 9:48 AM
Caladrius Biosciences to Host First Quarter 2021 Financial Results Conference Call on Thursday, May 6, 2021 at 4:30 p.m. Eastern TimeCaladrius Biosciences to Host First Quarter 2021 Financial Results Conference Call on Thursday, May 6, 2021 at 4:30 p.m. Eastern Time
finance.yahoo.com - April 29 at 9:30 AM
A Buy the Dip Stock Trigger in Caladrius Biosciences IncA Buy the Dip Stock Trigger in Caladrius Biosciences Inc
cmlviz.com - April 24 at 1:20 PM
Is It Safe to Invest in Caladrius Biosciences, Inc. (NASDAQ:CLBS) Now?Is It Safe to Invest in Caladrius Biosciences, Inc. (NASDAQ:CLBS) Now?
stocksregister.com - April 24 at 1:20 PM
Caladrius Biosciences, Inc. (NASDAQ:CLBS) Could Soar to Much Higher Prices in Coming MonthsCaladrius Biosciences, Inc. (NASDAQ:CLBS) Could Soar to Much Higher Prices in Coming Months
marketingsentinel.com - April 20 at 8:50 AM
Caladrius Biosciences, Inc. (NASDAQ:CLBS) Short Interest Down 17.9% in MarchCaladrius Biosciences, Inc. (NASDAQ:CLBS) Short Interest Down 17.9% in March
americanbankingnews.com - April 19 at 4:27 AM
Caladrius Biosciences, Inc. (NASDAQ:CLBS) – An Analysis Is What You NeedCaladrius Biosciences, Inc. (NASDAQ:CLBS) – An Analysis Is What You Need
stocksregister.com - April 13 at 1:38 PM
Caladrius Biosciences, Inc. (NASDAQ:CLBS) Forecast to gain 506.06% to hit Consensus price targetCaladrius Biosciences, Inc. (NASDAQ:CLBS) Forecast to gain 506.06% to hit Consensus price target
marketingsentinel.com - April 12 at 2:11 PM
Caladrius Biosciences, Inc. (NASDAQ:CLBS) Stock: Up 52% Since Low, This Stock Is Just Getting Warmed UpCaladrius Biosciences, Inc. (NASDAQ:CLBS) Stock: Up 52% Since Low, This Stock Is Just Getting Warmed Up
stocksregister.com - March 29 at 1:57 PM
Caladrius Biosciences Granted Orphan Drug Designation for CLBS12 for the Treatment of Buergers DiseaseCaladrius Biosciences Granted Orphan Drug Designation for CLBS12 for the Treatment of Buerger's Disease
benzinga.com - March 9 at 12:46 AM
Caladrius Biosciences Announces Orphan Drug Designation for CLBS12 for the Treatment of Buerger’s Disease Nasdaq:CLBSCaladrius Biosciences Announces Orphan Drug Designation for CLBS12 for the Treatment of Buerger’s Disease Nasdaq:CLBS
compsmag.com - March 8 at 2:45 PM
Is the Options Market Predicting a Spike in Caladrius Biosciences (CLBS) Stock?Is the Options Market Predicting a Spike in Caladrius Biosciences (CLBS) Stock?
finance.yahoo.com - March 8 at 2:45 PM
Caladrius Biosciences Announces Orphan Drug Designation for CLBS12 for the Treatment of Buerger’s DiseaseCaladrius Biosciences Announces Orphan Drug Designation for CLBS12 for the Treatment of Buerger’s Disease
finance.yahoo.com - March 8 at 9:45 AM
Caladrius Biosciences, Inc. (CLBS) Upgraded to Buy: What Does It Mean for the Stock?Caladrius Biosciences, Inc. (CLBS) Upgraded to Buy: What Does It Mean for the Stock?
finance.yahoo.com - March 4 at 12:50 PM
Caladrius Biosciences to Present at the H.C. Wainwright Global Life Sciences Virtual ConferenceCaladrius Biosciences to Present at the H.C. Wainwright Global Life Sciences Virtual Conference
finance.yahoo.com - March 3 at 10:26 AM
Caladrius Biosciences, Inc. (CLBS) CEO David Mazzo on Q4 2020 Results - Earnings Call TranscriptCaladrius Biosciences, Inc. (CLBS) CEO David Mazzo on Q4 2020 Results - Earnings Call Transcript
seekingalpha.com - February 27 at 10:05 PM
Caladrius Biosciences Reports Fourth Quarter and Full Year 2020 Financial Results and Provides ...Caladrius Biosciences Reports Fourth Quarter and Full Year 2020 Financial Results and Provides ...
apnews.com - February 25 at 7:01 PM
Caladrius Biosciences Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business UpdateCaladrius Biosciences Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
finance.yahoo.com - February 25 at 7:01 PM
DateCompanyBrokerageAction
5/15/2020Baudax BioJMP SecuritiesInitiated Coverage
5/11/2020Baudax BioOppenheimerLower Price Target
2/21/2020Baudax BioPiper SandlerBoost Price Target
11/22/2019Baudax BioJanney Montgomery ScottInitiated Coverage
11/22/2019Baudax BioPiper Jaffray CompaniesInitiated Coverage
9/24/2019Emmaus Life SciencesDawson JamesDowngrade
3/9/2021Caladrius BiosciencesBrookline Capital ManagementBoost Price Target
1/19/2021Caladrius BiosciencesHC WainwrightReiterated Rating
5/15/2020Caladrius BiosciencesChardan CapitalReiterated Rating
5/14/2019Caladrius BiosciencesWBB SecuritiesInitiated Coverage
(Data available from 5/9/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.